Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: Measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 854, Issue 1-2, 2007, Pages 245-259

  van den Broek, Irene ^a   Sparidans, Rolf W ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Enzymatic digestion; LC MS MS; Peptides; Quantification

Indexed keywords

ANTIBIOTICS; ENZYME ACTIVITY; EXTRACTION; METABOLITES; PLASMA (HUMAN); STANDARDS; VIRUSES;

CHYMOTRYPTIC FRAGMENTS; ENZYMATIC DIGESTION; SOLID PHASE EXTRACTION (SPE);

PEPTIDES;

DRUG METABOLITE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; ISOTOPE;

AMIDATION; ARTICLE; DRUG STABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; METABOLITE; METHODOLOGY; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; HYDROLYSIS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; TANDEM MASS SPECTROMETRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34250863316     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.04.026     Document Type: Article

References (26)

1. Aguiar M., Gibbs B.F., and Masse R. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 818 (2005) 301
2. Chang D., Kolis S.J., Linderholm K.H., Julian T.F., Nachi R., Dzerk A.M., Lin P.P., Lee J.W., and Bansal S.K. J. Pharm. Biomed. Anal. 38 (2005) 487
3. Dai S., Song H., Dou G., Qian X., Zhang Y., Cai Y., Liu X., and Tang Z. Rapid Commun. Mass Spectrom. 19 (2005) 1273
4. Delinsky D.C., Hill K.T., White C.A., and Bartlett M.G. Rapid Commun. Mass Spectrom. 18 (2004) 293
5. Delinsky D.C., Hill K.T., White C.A., and Bartlett M.G. Biomed. Chromatogr. 18 (2004) 700
6. Feng W.Y., Chan K.K., and Covey J.M. J. Pharm. Biomed. Anal. 28 (2002) 601
7. Kobayashi N., Kanai M., Seta K., and Nakamura K. J. Chromatogr. B Biomed. Appl. 672 (1995) 17
8. Song K.H., An H.M., Kim H.J., Ahn S.H., Chung S.J., and Shim C.K. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 775 (2002) 247
9. Tuthill C.W., Rudolph A., Li Y., Tan B., Fitzgerald T.J., Beck S.R., and Li Y.X. AAPS PharmSciTech 1 (2000) E11
10. van den Broek I., Sparidans R.W., Huitema A.D.R., Schellens J.H.M., and Beijnen J.H. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 837 (2006) 49
11. Yamaguchi K., Takashima M., Uchimura T., and Kobayashi S. Biomed. Chromatogr. 14 (2000) 77
12. Darby S.M., Miller M.L., Allen R.O., and LeBeau M. J. Anal. Toxicol. 25 (2001) 8
13. Bunk D.M., and Welch M.J. J. Am. Soc. Mass Spectrom. 8 (1997) 1247
14. Ji Q.C., Gage E.M., Rodila R., Chang M.S., and El-Shourbagy T.A. Rapid Commun. Mass Spectrom. 17 (2003) 794
15. Ji Q.C., Rodila R., Gage E.M., and El-Shourbagy T.A. Anal. Chem. 75 (2003) 7008
16. Barr J.R., Maggio V.L., Patterson Jr. D.G., Cooper G.R., Henderson L.O., Turner W.E., Smith S.J., Hannon W.H., Needham L.L., and Sampson E.J. Clin. Chem. 42 (1996) 1676
17. Zhang F., Bartels M.J., and Stott W.T. Rapid Commun. Mass Spectrom. 18 (2004) 491
18. Zhang F., Bartels M.J., Brodeur J.C., and Woodburn K.B. Environ. Toxicol. Chem. 23 (2004) 1408
19. Kuhn E., Wu J., Karl J., Liao H., Zolg W., and Guild B. Proteomics 4 (2004) 1175
20. Barnidge D.R., Goodmanson M.K., Klee G.G., and Muddiman D.C. J. Proteome Res. 3 (2004) 644
21. Aguiar M., Masse R., and Gibbs B.F. Anal. Biochem. 354 (2006) 175
22. Edelhoch H. Biochemistry 6 (1967) 1948
23. http://www.fda.gov/cder/guidance/4252fnl.htm, Guidance for industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP, May 2001.
24. http://www.emea.eu.int/humandocs/PDFs/EPAR/fuzeon/169503en6.pdf, Scientific discussion for the approval of Fuzeon European Medicines Agency (EMEA), 2005.
25. http://www.rocheuk.com/productDB/Documents/rx/spc/fuzeon_SPC.pdf, Summary of product characteristics; Fuzeon Roche registration ltd, UK 2005.
26. Barnidge D.R., Hall G.D., Stocker J.L., and Muddiman D.C. J. Proteome Res. 3 (2004) 658